Rossari Biotech Q2 FY27: Record revenue Rs 698 cr, up 19% YoY

Compliance View source PDF Explain this filing

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹455.00

prior close

₹452.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.7%-2.7% vs market

Specialty Chemicals peers, median of 101sector-1.8%-2.6% vs sector

On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.0

15m

-1.3

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4-1.7-2.7-1.8-2.6

Next day

-8.6-4.2-4.3-4.8-3.7

-5.7-5.2-0.5-5.7+0.0

-8.8-7.4-1.4-9.0+0.2

-10.6-7.0-3.6-8.9-1.7

-10.5-5.5-5.0-7.1-3.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 101Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Rossari Biotech posted highest-ever quarterly revenue of Rs 697.6 cr in Q2 FY27, up 19% YoY. Record EBITDA of Rs 87 cr, up 20.9% YoY, margins at 12.5%. PAT was Rs 38.9 cr, subdued due to higher depreciation. Exports surged 33.8% YoY to Rs 216.4 cr. Net debt fell to Rs 221 cr from Rs 281 cr. Board approved a new greenfield plant in Saudi Arabia. H1 FY27 revenue grew 23.4% YoY to Rs 1,394.8 cr.

Likely market impact

Record revenue, EBITDA and exports with falling debt and a new Saudi plant point to positive growth momentum for shareholders.